Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAENNEC is a pharmaceutical preparation derived from human placenta that contains a rich array of bioactive substances including growth factors, cytokines, amino acids, peptides, minerals, and vitamins. It's primarily known for its hepatoprotective (liver-protecting) properties but has found applications in various medical and aesthetic fields. ## Composition and Manufacturing LAENNEC is manufactured through a unique extraction technology that preserves the bioactive components of human placenta. The product contains human placenta hydrolysate (112mg per 2ml) along with additives such as pepsin (of porcine origin) and trace amounts of gastric mucosal extract from pigs. ## Medical Applications The primary medical indication for LAENNEC is improving hepatic function in chronic liver diseases. Clinical studies have demonstrated its effectiveness in: - Reducing serum transaminase (GOT, GPT) levels in patients with chronic hepatitis and liver cirrhosis - Inhibiting experimental liver injury - Providing anti-fatty liver effects - Inhibiting liver fibroplasia - Potentially affecting HCV-RNA levels in certain combination therapies ## Aesthetic and Therapeutic Uses Beyond its liver-related applications, LAENNEC is widely used for: - Anti-aging and skin rejuvenation - Improving skin tone and texture - Reducing wrinkles and gravitational ptosis - Treating skin conditions like eczema, acne, psoriasis, and atopic dermatitis - Post-procedure recovery (after peeling, plastic surgery) - Enhancing ligament healing by suppressing immune responses and reducing degenerative changes - Treating chronic fatigue syndrome - Immunomodulation ## Administration LAENNEC can be administered through various routes: - Intramuscular injection (typically 2-4 ml per session) - Intravenous injection (8-10 ml via dropper) - Subcutaneous injection - Mesotherapy - Pharmacopuncture (microdoses at biologically active points) The standard dosage is 2 ml once daily, which can be increased to 2-3 times daily according to symptoms. A typical treatment course consists of 10-15 sessions. ## Safety and Sourcing The placenta used in LAENNEC comes from healthy mothers who had natural, safe deliveries with no diseases or pathologies. Both mother and child undergo thorough medical screening, and donors remain under medical supervision for several years after delivery. LAENNEC is manufactured by Japan Bio Products Co., Ltd. and is approved as a pharmaceutical in Japan by the Ministry of Health, Labour, and Welfare.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LAENNEC.